Key ACTEMRA/RoACTEMRA publication summaries
This section contains summaries of key publications relating to ACTEMRA/RoACTEMRA. These include Phase I, II and III clinical trials of ACTEMRA/RoACTEMRA for the treatment of patients with rheumatoid arthritis (RA), a review of the role of IL-6 in the regulation of hepcidin, the iron regulatory hormone, and also a review discussing the relationship between inflammation, lipid levels and cardiovascular disease risk in patients with RA. Click on a publication title to read the summary.
Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: The first phase IIIb real-life study (TAMARA)
GR Burmester et al. Ann Rheum Dis 2010 [ePub ahead of print].
Efficacy of methotrexate in comparison to biologics in rheumatoid arthritis
R Rau Clin Exp Rheumatol 2010; 28 (5 Suppl. 61):S58–S64.
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate at 1 year: The LITHE study
JL Kremer et al. Arthritis Rheum 2010 [ePub ahead of print].
Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs
GJ Bergman et al. Semin Arthritis Rheum 2010; 39:425–441.
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study
G Jones et al. Ann Rheum Dis 2010; 69:88–96.
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
N Nishimoto et al. Mod Rheumatol 2009; 19:12–19.
Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
N Nishimoto et al. Ann Rheum Dis 2009; 68:1580–1584.
Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions
E Choy & N Sattar Ann Rheum Dis 2009; 68:460–469.
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre randomised placebo-controlled trial (RADIATE study)
P Emery et al. Ann Rheum Dis 2008; 67:1516–1523.
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
MC Genovese et al. Arthritis Rheum 2008; 58:2968–2980.
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
JS Smolen et al. Lancet 2008; 371:987–997.
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
N Nishimoto et al. Ann Rheum Dis 2007; 66:1162–1167.
Double-blind randomized controlled clinical trial of the interleukin‑6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
RN Maini et al. Arthritis Rheum 2006; 54:2817–2829.
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial
N Nishimoto et al. Arthritis Rheum 2004; 50:1761–1769.
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin
E Nemeth et al. J Clin Invest 2004; 113:1271–1276.
Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study
N Nishimoto et al. J Rheumatol 2003; 30:1426–1435.
Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys
M Mihara et al. Clin Immunol 2001; 98:319–326.